Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alexion Pharmaceuticals Inc Raises FY 2013 Guidance

Thursday, 25 Jul 2013 06:30am EDT 

Alexion Pharmaceuticals Inc announced that it is raising its fiscal 2013 revenue guidance from the previous range of $1.505 to $1.520 billion, now to the higher range of $1.520 to $1.530 billion. The upward revision reflects continued global growth of Soliris in PNH and growth from the ongoing launch of Soliris in aHUS. Guidance for fiscal 2013 non-GAAP EPS is also being revised upward, from the previous range of $2.87 to $2.97, now to the higher range of $2.97 to $3.02, based on a forecast of 204 million diluted shares outstanding. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $1.518 billion and EPS of $2.96 for fiscal 2013. 

Company Quote

-1.88 -1.15%
17 Sep 2014